Coastal Investment Advisors Inc. Purchases 485 Shares of Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Coastal Investment Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 3.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,914 shares of the company’s stock after buying an additional 485 shares during the period. Johnson & Johnson accounts for about 0.7% of Coastal Investment Advisors Inc.’s portfolio, making the stock its 26th largest position. Coastal Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $2,347,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Newfound Research LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $28,000. Essex Investment Management Co. LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Crewe Advisors LLC raised its position in shares of Johnson & Johnson by 909.1% in the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the last quarter. Dimension Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $53,000. Finally, IMA Wealth Inc. raised its position in Johnson & Johnson by 26.8% during the 3rd quarter. IMA Wealth Inc. now owns 478 shares of the company’s stock worth $71,000 after buying an additional 101 shares during the last quarter. Institutional investors and hedge funds own 61.26% of the company’s stock.

In other news, COO Michael E. Sneed sold 54,662 shares of the business’s stock in a transaction dated Wednesday, December 9th. The stock was sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the completion of the transaction, the chief operating officer now directly owns 110,741 shares of the company’s stock, valued at $16,935,621.13. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.27% of the stock is owned by corporate insiders.

A number of equities analysts have issued reports on the stock. Morgan Stanley raised their price target on shares of Johnson & Johnson from $170.00 to $178.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 15th. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Finally, BidaskClub raised shares of Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $165.50.

Shares of NYSE:JNJ opened at $157.89 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The firm has a market capitalization of $415.65 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.30 and a beta of 0.68. The firm’s 50-day moving average is $152.86 and its two-hundred day moving average is $148.31. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $161.32.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.12 earnings per share. Analysts expect that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be paid a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, February 22nd. This represents a $4.04 dividend on an annualized basis and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: What is an inverted yield curve?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.